JN-Intl. acquires vaccine facilities from Pfizer

Biopharmaceutical firm JN Intl.acquired Biocor, a subsidiary of Pfizer, Inc.

The three-building facility enables JN to expand its ability to increase vaccine supplies. The move is intended to help reduce time to market for the company's Meningococcal meningitis serotypes A, C, Y and W-135.
Companies in this article
More in Home